Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease ...

Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005 ...

LUND, Sweden, June 9, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event on Guillain-Barré syndrome (GBS) on ...

As Maharashtra registers over 100 cases of Guillain-Barre Syndrome (GBS), the Director General Indian Council of Medical Research Dr Rajiv Bahl said that the cases are under investigation as a ...

GBS outbreak: Guillain-Barre Syndrome cases in Pune under investigation, says DG ICMR. x. ... "Samples of stool and blood of those infected are being tested at the NIV Pune lab, ...

Guillain Barre Syndrome. PM Modi. NIV finds norovirus and Campylobacter bacteria in 21 GBS samples from Pune. ... bacteriological and virological analyses to the state lab.

Guillain-Barré Syndrome In Pune: Meat & Seafood Free Of GBS-Causing Bacteria, Report Shows ... The meat shops were inspected and samples of raw meat were sent to the labs for testing.

BRISBANE, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...